(Q33904297)

29 July 2017

1 reference

title

Prostate-specific membrane antigen: present and future applications (English)

1 reference

29 July 2017

Chang SS

1

1 reference

29 July 2017

Gaudin PB

series ordinal

2

1 reference

29 July 2017

Reuter VE

series ordinal

3

1 reference

29 July 2017

Heston WD

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

29 July 2017

1 reference

29 July 2017

55

1 reference

29 July 2017

5

1 reference

29 July 2017

622-629

1 reference

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Prostate-specific membrane antigen: evidence for the existence of a second related human gene

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900600-7

7 January 2021

10.1016/S0090-4295(99)00600-7

Identifiers

DOI

1 reference

29 July 2017

1 reference